CHICAGO, AstraZeneca today announced details of two new investigational cancer therapies at the American Society of Clinical Oncology (ASCO) meeting. AZD2281 (KU-0059436) is a small molecule inhibitor of Poly-ADP Ribose Polymerase (PARP).
PARP is an enzyme involved in Base Excision Repair which is a key pathway in the repair of DNA single-stranded breaks. Inhibiting this DNA repair mechanism, in tandem with a defective DNA repair gene like BRCA1 or BRCA2, is thought to lead to double-stranded DNA breaks that tumor cells are unable to repair, resulting in tumor cell death.
AZD2281 has been studied in a range of tumor types in Phase I studies. The study presented today at ASCO showed that treatment with AZD2281 led to inhibition of PARP functional activity in both surrogate and tumor tissue, and reported that strong signals were detected in hereditary ovarian cancer. Between 5% and 10% of all breast and ovarian cancers are believed to be associated with mutations in the BRCA1 or BRCA2 mutations.
Women with BRCA mutations are reported to have up to an 87% risk of developing breast cancer, and up to a 44% risk of developing ovarian cancer by the age of 70.Professor James Carmichael of AstraZeneca said, "We are delighted to be working with The Royal Marsden Hospital and Netherlands Cancer Institute (NKI) on this study, which is at the forefront of research into new targeted treatments for cancer.
The early results we have seen in patients with hereditary ovarian cancer have encouraged us to move rapidly into the next phase of development for this compound."AZD0530, another investigational compound in Phase II clinical development is an inhibitor of Src in tumours. Src was the first cancer-causing gene to be discovered in the 1970s. Src kinases are a family of molecules that play an important role in cancer growth, spread, apoptosis and cell proliferation.
By inhibiting Src it is hoped that cancer prog
'"/>Page: 1 2 3 Related medicine news :1.
Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke2.
New Drug Application Submitted for Investigational Antibiotic Doripenem3.
Fibroids unlikely to Turn Cancerous
4.
Virus Level could Predict Cervical Cancer Risk
5.
Cancer Doctors Okays Controversial Prostate Therapy6.
Potential New Cancer Gene Identified7.
Consensus on "Combination Therapy" for Breast Cancer
8.
Cancers of Colon & Rectum linked to Cigarette Smoking9.
Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos10.
The Cancer Rumour mill working over time11.
Cancer drugs in development nearly doubled since 1995